KR20230052956A - 변형된 il-18 폴리펩티드 및 이의 용도 - Google Patents

변형된 il-18 폴리펩티드 및 이의 용도 Download PDF

Info

Publication number
KR20230052956A
KR20230052956A KR1020237009427A KR20237009427A KR20230052956A KR 20230052956 A KR20230052956 A KR 20230052956A KR 1020237009427 A KR1020237009427 A KR 1020237009427A KR 20237009427 A KR20237009427 A KR 20237009427A KR 20230052956 A KR20230052956 A KR 20230052956A
Authority
KR
South Korea
Prior art keywords
modified
polypeptide
residue
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237009427A
Other languages
English (en)
Korean (ko)
Inventor
비자야 라가반 파타비라만
베르톨트 크레프트
레기스 뵈링거
카밀 델론
클라우디아 페츠
알렉산더 프로흘
베노이트 호른슈페르거
장 필립 캐럴롯
제프리 윌리엄 보데
루이즈 마틸드 아레발로
아멜리 비더케어
안나 하이든
로베르토 이아코네
총칭 왕
Original Assignee
브라이트 피크 테라퓨틱스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 브라이트 피크 테라퓨틱스 아게 filed Critical 브라이트 피크 테라퓨틱스 아게
Publication of KR20230052956A publication Critical patent/KR20230052956A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
KR1020237009427A 2020-08-19 2021-08-19 변형된 il-18 폴리펩티드 및 이의 용도 Pending KR20230052956A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063067658P 2020-08-19 2020-08-19
US63/067,658 2020-08-19
PCT/IB2021/000574 WO2022038417A2 (en) 2020-08-19 2021-08-19 Modified il-18 polypeptides and uses thereof

Publications (1)

Publication Number Publication Date
KR20230052956A true KR20230052956A (ko) 2023-04-20

Family

ID=78032459

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237009427A Pending KR20230052956A (ko) 2020-08-19 2021-08-19 변형된 il-18 폴리펩티드 및 이의 용도

Country Status (9)

Country Link
US (1) US20220056091A1 (https=)
EP (1) EP4200323A2 (https=)
JP (1) JP2023538422A (https=)
KR (1) KR20230052956A (https=)
CN (1) CN116368148A (https=)
AU (1) AU2021327861A1 (https=)
CA (1) CA3189327A1 (https=)
IL (1) IL300638A (https=)
WO (1) WO2022038417A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL272635B2 (en) 2017-09-06 2024-02-01 Univ Yale Variants of interleukin-18 and methods of use
JP2023550545A (ja) * 2020-11-02 2023-12-01 シムハ・アイエル－１８・インコーポレイテッド インターロイキン－１８バリアントおよび使用の方法
AU2023226512A1 (en) 2022-02-23 2024-08-29 Bright Peak Therapeutics Ag Immune antigen specific il-18 immunocytokines and uses thereof
WO2024044780A1 (en) * 2022-08-26 2024-02-29 Sutro Biopharma, Inc. Interleukin-18 variants and uses thereof
WO2024102587A2 (en) * 2022-11-11 2024-05-16 Mural Oncology, Inc. Interleukin 18 variants
US20250186594A1 (en) * 2023-08-23 2025-06-12 Bright Peak Therapeutics Ag Il-18 polypeptides modified with polymers
US12134635B1 (en) 2023-12-29 2024-11-05 Sonnet BioTherapeutics, Inc. Interleukin 18 (IL-18) variants and fusion proteins comprising same
WO2025151273A1 (en) * 2024-01-08 2025-07-17 Adimab, Llc Il-18 polypeptides and uses thereof
WO2025242835A1 (en) 2024-05-22 2025-11-27 Ose Immunotherapeutics Molecules comprising masking linkers and uses thereof for the treatment of cancer
WO2026083296A1 (en) 2024-10-16 2026-04-23 Bright Peak Therapeutics Ag Trispecific compositions comprising il-18, vegf binding domains, and pd-1 binding domains

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002101049A2 (en) * 2001-03-08 2002-12-19 Ares Trading S.A. Interleukin-18 mutants, their production and use
EP2261244A3 (en) * 2003-04-15 2011-02-23 Glaxosmithkline LLC Human il-18 substitution mutants and their conjugates
US20160107999A1 (en) 2013-05-24 2016-04-21 Synaffix B.V. Substituted azadibenzocyclooctyne compounds and their use in metal-free click reactions
US10266502B2 (en) 2014-01-24 2019-04-23 Synaffix B.V. Process for the cycloaddition of a halogenated 1,3-dipole compound with a (hetero)cycloalkyne
JP7128121B2 (ja) 2016-06-28 2022-08-30 ヴェンタナ メディカル システムズ， インク． Ｉｈｃ及びｉｓｈアッセイにおけるシグナル増幅のためのクリックケミストリーの応用
IL272635B2 (en) * 2017-09-06 2024-02-01 Univ Yale Variants of interleukin-18 and methods of use

Also Published As

Publication number Publication date
WO2022038417A2 (en) 2022-02-24
AU2021327861A1 (en) 2023-05-04
CN116368148A (zh) 2023-06-30
US20220056091A1 (en) 2022-02-24
JP2023538422A (ja) 2023-09-07
EP4200323A2 (en) 2023-06-28
WO2022038417A3 (en) 2022-04-21
IL300638A (en) 2023-04-01
CA3189327A1 (en) 2022-02-24
AU2021327861A9 (en) 2023-07-06

Similar Documents

Publication Publication Date Title
KR20230052956A (ko) 변형된 il-18 폴리펩티드 및 이의 용도
US12521441B2 (en) Modified IL-2 polypeptides and uses thereof
KR100668546B1 (ko) 수용체에 결합하는 펩티드 및 화합물
US20230357342A1 (en) Modified il-18 polypeptides
CN103450348B (zh) 一种促红细胞生成素模拟肽、其制备方法和用途
JP2016504335A (ja) Ａｐｊ受容体アゴニストおよびその使用
US20230303649A1 (en) Modified il-2 polypeptides for treatment of inflammatory and autoimmune diseases
JP2025508824A (ja) 活性化可能なｉｌ－１８ポリペプチド
CN117616036A (zh) 用于治疗炎性疾病和自身免疫性疾病的修饰的il-2多肽
DE102020125465A1 (de) Amidierte Peptide und ihre deamidierten Gegenstücke, die durch nicht-HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
KR20180100133A (ko) 질환 및 장애를 치료하기 위한 인터류킨-10을 사용하는 방법

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902